Attitude of Japanese palliative care specialists towards adjuvant analgesics cancer-related neuropathic pain refractory to opioid therapy: A nationwide cross-sectional survey

Hiromichi Matsuoka, Keita Tagami, Keisuke Ariyoshi, Shunsuke Oyamada, Yoshiyuki Kizawa, Akira Inoue, Atsuko Koyama

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Cancer-related neuropathic pain (CNP) requires therapy involving multiple pharmaceuticals, including anticonvulsants and antidepressants; however, strong evidence to support this practice is limited. This study is a cross-sectional questionnaire-based survey. As the standard dose of adjuvant analgesics for CNP refractory to opioid therapy is not clear, the purpose of this study is to clarify the opinions of specialists about the usage of duloxetine and pregabalin for patients with CNP refractory to opioid therapy. Two hundred and eight certified palliative care specialists were surveyed and a total of 87 (42%) responses were analyzed. Twenty-five percent of specialists had considered increasing duloxetine doses up to 60 mg/day and 58% had considered increasing pregabalin doses up to 300 mg/day for CNP refractory to opioid therapy. However, 23% of the specialists succeeded in increasing duloxetine doses up to 60 mg/day and 17% in increasing pregabalin doses up to 300 mg/day, respectively.

Original languageEnglish
Pages (from-to)486-490
Number of pages5
JournalJapanese journal of clinical oncology
Volume49
Issue number5
DOIs
Publication statusPublished - 2019 May 1

Keywords

  • Adjuvant analgesics
  • Cancer-related neuropathic pain
  • Duloxetine
  • Nationwide cross-sectional survey
  • Pregabalin

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Attitude of Japanese palliative care specialists towards adjuvant analgesics cancer-related neuropathic pain refractory to opioid therapy: A nationwide cross-sectional survey'. Together they form a unique fingerprint.

Cite this